BDX heads into fiscal Q1 with the consensus estimate calling for $5.15 billion in revenues and $2.82 in EPS. BD's Medical segment is supported by biologics and GLP-1 demand plus adoption of new ...

MORRISVILLE, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) and Pharmosa Biopharm (Pharmosa) today announced that they have entered into an ...

They serve as sustained-release drug delivery systems as they can encapsulate various bioactive substances, including drugs, antigens, and even cells. Hydrogels are better drug delivery alternatives ...

DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...